Since the concept of personalised cancer therapies first emerged, the picture has become so much more complex and challenging.
If Tomasetti and Vogelstein had not used the words Â“bad luckÂ” in their paper on how Â‘variation in cancer risk among tissues can be explained by the number of stem cell divisionsÂ’, the media might not have covered the story the way they did. In this interview with The Cancer Letter, Bertram Kramer, head of Cancer Prevention at the US National Cancer Institute, tries to clear up some of the confusion.
Early detection, disease prognosis, a guide to treatment, a key to unlock the secrets of how cancers evolve. Researchers have high hopes for what they can learn from the biological detritus shed by primary tumours and metastases.